Generic cannabinoid overview from Ackrell Capital with no evident investigative leads

ACKRELL CHAPTER II Cannabis Science 101 antidepressant, antiemetic, anti-inflammatory, antinausea and antispasmodic. It also is believed to have therapeutic applications, such as appetite stimulation, bronchodilation, neuroprotection and pain relief. CBD (Cannabidiol: CBD is considered to be the second most abundant cannabinoid in canna- bis. It is nonpsychoactive and is believed to counteract the psychoactive effects of THC. CBD also is believed to have wide-ranging medicinal benefits: analgesic, antianxiety, antibacterial, anticancer, anti- convulsant, antidepressant, antiemetic, anti-inflammatory, anti-insomnia, anti-ischemic, antipsychotic and antispasmodic. In addition, CBD is believed to have therapeutic applications, including appetite stimulation, bone-growth stimulation, immunosuppression and neuroprotection. CBD can be derived from many cannabis strains, including low-THC strains ordinarily grown to produce industrial hemp products. CBC (Cannabichromene: CBC is thought to be the third most abundant cannabinoid in canna- bis and is nonpsychoactive. Like THC and CBD, CBC is believed to have several medicinal bene- fits, including analgesic, antibacterial, anticancer, antidepressant, antifungal, anti-inflammatory and anti-insomnia. CBC is also used as a therapeutic bone-growth stimulant. Ongoing research seeks to determine the role of CBC in reducing gastrointestinal inflammation. CBC may also have applications in pain management—in addition to binding to the CB1 and CB2 endocannabinoid receptors, it has been shown to interact with certain pain receptors. CBG (Cannabigerol: CBG is nonpsychoactive and is believed to have several medicinal benefits— analgesic, antibacterial, anticancer, antidepressant and antifungal—as well as a therapeutic application for bone-growth stimulation. CBG is present primarily during the early stages of the cannabis plant’s growth cycle; only small amounts can be extracted from the plant during its flowering stage (although strains of cannabis have recently been bred to have high levels of CBG). CBG is believed to partially counteract the psychoactive effects of THC and to decrease anxiety and muscle tension. CBGA (Cannabigerolic Acid: CBGA is a nonpsychoactive precursor to all other cannabinoids, including THC, CBD, CBC and CBG. Much of a cannabis plant’s CBGA ultimately transforms into other cannabinoids through the chemical process of decarboxylation. CBGA is used for analgesic and anti-inflammatory applications. Certain cannabis strains cultivated to produce industrial hemp prod- ucts are believed to contain high levels of CBG relative to other strains. CBN Cannabinol: CBN has been shown to produce some psychoactive effects and is believed to have several medicinal benefits, such as analgesic, antibacterial, anticonvulsive, anti-inflammatory and anti-insomnia. Unlike many other cannabinoids, CBN is not derived directly from CBGA decarboxyl- ation; instead, it results from THC degradation. The CBN level of a cannabis plant is sometimes used as a measure of the plant’s overall quality for consumption. THCA _ Delta-9-Tetrahydrocannabinolic Acid: THCA is found abundantly in raw cannabis flower and is the precursor to THC. THCA is nonpsychoactive and is believed to have several medicinal benefits, including anticancer, anti-inflammatory and antispasmodic. THCA decarboxylates into THC through drying or application of intense heat, such as the heat applied during smoking or vaporizing the cannabis plant. © 2017 Ackrell Capital, LLC | Member FINRA/SIPC 21 HOUSE_OVERSIGHT_024657